訊聯生物科技股份有限公司 Approved
最後更新時間 2025/07/03 , 07:31 AM
最後更新時間 2025/07/03 , 07:31 AM
負責人
Cai,Zheng-Xian
統一編號
70836411
成立日期
2000/08/17
資本額
NT$2,000,000,000
實收資本額
NT$531,211,910
股票代號
1784
電話
02-27951777
地址
1F, No. 28, Ln. 36, Sinhu 1st Rd., Neihu Dist., Taipei City, 114, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Cai,Zheng-Xian Chairman 3.55%
Zhang,Wen-Zheng Director 1.81%
Liang,Shi-Ming Director 2.28% KUN LUN INVESTMENT CO., LTD.
Zhang,Han-Dong Director 5.08% GENETICS GENERATION ADVANCEMENT CORP. (GGA CORP.)
Huang,Shao-Hua Independent Director 0.00%
Vacancy Independent Director 0.00%
Li,Yi-Da Independent Director 0.00%
營業項目
  • Other Human Health Activities Not Elsewhere Classified(869913)
  • Other Human Health Activities Not Elsewhere Classified(869914)
  • 公司歷程
    員工人數
    財務報表
    項目 2025 2024 2023
    Operating income 290,800 1,222,030 1,127,304
    Operating cost 133,360 536,263 489,027
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 157,440 685,767 638,277
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 157,440 685,767 638,277
    Operating expenses 155,941 623,378 553,584
    Other gain (loss), net - - -
    Operating profit (loss) 1,499 62,389 84,693
    Non-operating income and expenses 9,756 39,851 22,391
    Net profit (loss) before tax 11,255 102,240 107,084
    Income tax expense (benefits) 7,971 32,375 25,687
    Net profit (loss) of ongoing business for the current period 3,284 69,865 81,397
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 3,284 69,865 81,397
    Other comprehensive profit (loss), net -1,881 -3,872 -944
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 1,403 65,993 80,453
    Net profit (loss) attributable to owners of parent company 15,014 83,702 78,399
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests -11,730 -13,837 2,998
    Comprehensive profit (loss) attributable to owners of parent company 14,353 82,742 77,657
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests -12,950 -16,749 2,796
    Basic earnings per share (yuan) 0 1 1
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -37,828 176,493 153,095
    Net cash inflows (outflows) from investing activities 10,264 -778,147 -409,930
    Net cash inflow (outflow) from financing activities -21,158 605,463 333,981
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 95 491 -268
    Increase (decrease) in cash and cash equivalents in the current period -48,627 4,300 76,878
    Beginning balance of cash and cash equivalents 242,792 238,492 161,614
    Ending balance of cash and cash equivalents 194,165 242,792 238,492
    項目 2025 2024 2023
    Current asset 2,009,067 1,999,501 1,268,261
    Non-current asset 1,128,895 1,156,740 1,080,378
    Total asset 3,137,962 3,156,241 2,348,639
    Current liability 453,264 395,008 324,918
    Non-current liability 374,051 365,391 301,548
    Total liability 827,315 760,399 626,466
    share capital 531,212 531,212 496,269
    Equity - secruity token - - -
    capital reserve 762,801 761,734 666,206
    retained earning 66,066 125,363 110,941
    Other equity -8,643 -7,982 -6,416
    Treasury stock -93,998 -75,700 -79,369
    Total equity attributable to owners of parent company 1,257,438 1,334,627 1,187,631
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests 1,053,209 1,061,215 534,542
    Total Equity 2,310,647 2,395,842 1,722,173
    Share capital awaiting retirement (unit: share) 0 0 -
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 2,513,401 2,293,401 2,330,000
    Net asset value per share 24 26 25
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • 天使肌泌
  • 訊聯基因
  • 訊聯基因數位
  • 訊聯細胞智藥
  • BiONET訊聯細胞智藥
  • BiONET THERAPEUTICS
  • 訊聯細胞
  • BiONET訊聯細胞
  • BiONET
  • PetStem
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Pay for the project
    2010
  • Compensation for damage
    2012, 2013, 2015, 2020
  • Infringement damage compensation
    2008, 2009
  • Payment order
    2012
  • Fair Trading Act
    2009, 2010
  • Petition for trial
    2009, 2011
  • Invalidating Judgment
    2006, 2009
  • Compensation for damage
    2016
  • Compensation for damage, etc.
    2008, 2010, 2011
  • Infringement damage compensation
    2010
  • Petition filed for public summons
    2008
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。